Additionally, the expression of xCT/SLC7A11 in patient glioma tissue correlates with the peritumoral glutamate response to sulfasalazine, suggesting its potential as a predictive biomarker for the efficacy of sulfasalazine in modulating glutamate release [65]. The gene discussed is SLC7A11; the disease is glioma.